Soliris Reduces Blood Clots in PNH Patients By 92%, Study Shows
Posted on: Monday, 20 August 2007, 15:02 CDT
Patients with a rare blood disorder named paroxysmal nocturnal hemoglobinuria experienced a 92% reduction in the incidence of life-threatening blood clots following treatment with Alexion Pharmaceuticals's Soliris, according to an analysis of clinical studies.
Soliris is approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can cause severe anemia, disabling fatigue, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), kidney disease, impaired quality of life and thromboses.
The study, published online in Blood, the journal of the American Society of Hematology, analyzed data from 195 patients studied in the Soliris Phase II and Phase III trials. Patients were enrolled in the US, Europe, Australia and Canada and treated with Soliris for up to 54 months.
Soliris reduced hemolysis in all treated patients and reduced thrombosis by 92%, with three events during Soliris treatment compared to 39 events during the same period of time prior to treatment. The collection of thrombotic events was defined prospectively by clinical trial protocols.
Source: Datamonitor
Related Articles
- Blood Test Helps Guide Treatment, Can Impact Quality Of Life For Breast Cancer Patients
- Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment
- Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital
- Patients Dealing with Rising Cancer Treatment Costs
- Despite Morbidity Associated With Hypertension, Almost 65% of Newly Diagnosed Patients Do Not Receive Drug Treatment in the First 360 Days of Their Diagnosis
- Over 5,800 AIDS Patients in China Receive TCM Treatment
- Over 5,800 AIDS Patients in China Receiving TCM Treatment
- Study Identifies which Patients Will Not Respond to Treatment with Targeted Cancer Drug
- Studies Show Schizophrenia Patients Taking Atypicals Stayed on Treatment Longer Than Patients Taking Older, Typical Antipsychotics
 |
 |
User Comments (0)
RSS Feeds